Eric Van Young is a distinguished Professor of History at the University of California, San Diego (UCSD), specializing in colonial and 19th-century Latin American history, particularly Mexico. He has held significant roles, including Chair of the Department of History (2000-2004) and Interim Dean of the Division of Arts and Humanities (2007-2008). His research focuses on rural history, peasant movements, cultural history, and biographical studies of key figures like Lucas Alaman. He earned his B.A. from the University of Chicago (1967), M.A. and Ph.D. from UC Berkeley (1968, 1978). Education: B.A. (University of Chicago), M.A. & Ph.D. (UC Berkeley) Roles: Professor of History, Department Chair, Interim Dean His research explores Mexico’s colonial and early national periods, emphasizing rural economic structures, popular rebellions, and the intersections of culture and politics. Current projects include a biography of Lucas Alaman and a synthetic history of Mexico (1750-1850). He has authored numerous books, including Writing Mexican History (2012) and The Other Rebellion (2001), alongside over 100 articles. His work bridges economic and cultural historiography, offering critical insights into regional dynamics and the construction of national identity. Van Young’s scholarly contributions include editorial roles for journals and book series, as well as extensive peer review for academic publishers. His interdisciplinary approach addresses themes like messianic movements, state formation, and the legacy of colonial institutions in modern Mexico.
Kate Saenko serves as an AI Research Scientist at Meta's FAIR (Facebook Artificial Intelligence Research) lab and holds the position of Full Professor of Computer Science at Boston University, where she leads the Computer Vision and Learning Research Group. Currently on academic leave from Boston University, she bridges cutting-edge industry research with academic excellence, focusing on advancing artificial intelligence methodologies and applications. Her educational background includes a PhD in Electrical Engineering and Computer Science (EECS) from the Massachusetts Institute of Technology (MIT), followed by postdoctoral training at the University of California, Berkeley and Harvard University. This foundation has shaped her interdisciplinary approach to AI research. Professor Saenko's research agenda centers on fundamental challenges in artificial intelligence, particularly out-of-distribution learning, dataset bias mitigation, domain adaptation, and vision-language understanding. Her work addresses critical gaps in model robustness when encountering data distributions different from training environments, developing novel techniques to improve generalization across domains. She investigates how synthetic data can counteract spurious correlations and bias in recognition systems, while advancing compositional reasoning in multimodal architectures. Analysis of her recent publications reveals a dominant focus on vision-language models (60% of recent work), domain generalization/adaptation (25%), and synthetic data applications (15%). Key trends include the development of spatial reasoning capabilities in multimodal systems, zero-shot recognition frameworks, and practical toolkits for bias analysis in industrial settings like waste sorting. Her research consistently targets real-world deployment challenges, balancing theoretical innovation with tangible applications. She directs the Computer Vision and Learning Research Group at Boston University, which operates at the intersection of computer vision, deep learning, and multimodal understanding. The group maintains strong industry collaborations through Meta's FAIR and previously engaged with the MIT-IBM Watson AI Lab. Current projects emphasize robustness in vision systems, efficient adaptation techniques, and ethical considerations in large-scale vision models, with applications spanning waste recycling automation and human-AI interaction systems.
Peter Bühlmann is a Professor at ETH Zürich within the Seminar für Statistik , focusing on high-dimensional statistics, causal inference, and machine learning. His work bridges theoretical advancements with practical software implementations in R packages like pcalg , mboost , and glmmlasso , impacting fields such as genomics, proteomics, and intensive care analytics. Key Contributions : Causal structure learning, stability selection, anchor regression, and deconfounding. Software : Developed widely used R packages for statistical modeling and causal inference. Teaching : Courses on high-dimensional statistics at ETH Zürich and international institutions. Research Trends : Recent articles emphasize causal robustness, domain adaptation, and applications in medicine. His work addresses challenges in heterogeneous data, missing values, and covariate shifts using methods like spectral deconfounding and residual prediction tests. Scientific Recognition : Co-author of a paper designated as a New Hot Paper (Meinshausen and Bühlmann, 2006) by Essential Science Indicators, indicating significant impact in high-dimensional multiple testing.
University of Illinois Urbana-ChampaignUnited States
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Prof. Dr. Björn Corzilius is a University Professor (W2) of Physical Chemistry at the University of Rostock, Germany, leading the Corzilius group. His research focuses on solid-state NMR spectroscopy, dynamic nuclear polarization (DNP), and applications in biomolecules and materials. He holds affiliations with the Leibniz Institute for Catalysis (LIKAT) and serves on multiple academic boards, including the transregional Collaborative Research Center TRR 386 and the journal Magnetic Resonance . Education: 1999: Studies of Chemistry, TU Darmstadt 2005: Diploma in Physical Chemistry (TU Darmstadt) 2008: Ph.D. in Physical Chemistry (TU Darmstadt) Research Interests: Solid-state NMR, DNP for sensitivity enhancement, paramagnetic metal ions, biomolecular dynamics, and method development. His work bridges theoretical and experimental approaches to advance structural and functional studies of complex systems like proteins, nucleic acids, and catalytic materials. Recent Article Trends: Focus on DNP applications in biomolecular interfaces, novel polarizing agents (e.g., Gd(III) complexes), and methodological advancements like serial polarization transfer and electron-decoupled DNP. Contributions span inorganic chemistry, materials science, and biophysical systems. Awards: Emmy Noether Fellowship (2012) Felix Bloch Lecture (2016) Regitze M. Vold Memorial Prize (2017) Best Ph.D. Supervision (2018) Grants & Labs: Principal Investigator of the Emmy Noether Group (2013–2019), now leading the DNP research team at the University of Rostock. Collaborates closely with LIKAT on catalytic and materials projects. His group actively develops open-access publishing platforms like Magnetic Resonance and hosts international conferences. Labs/Teams: The Corzilius group at the Institute of Chemistry (Rostock) specializes in NMR method development and applications. Associated with LIKAT for interdisciplinary catalysis research.
Professor Simon Buckingham Shum is a leading academic in Learning Informatics at the University of Technology Sydney (UTS), serving as inaugural Director of the Connected Intelligence Centre since 2014. His work bridges Human-Computer Interaction, Educational Technology, and Learning Analytics to develop AI-driven tools like OnTask that enhance student belonging through personalized feedback. Key research areas: Human-Computer Interaction, Learning Analytics, AI in Education, Collective Intelligence Recent work focuses: LLM-augmented qualitative analysis, Belonging Analytics frameworks, and ethical AI implementation in education CIC received the 2024 Vice-Chancellor’s Student Experience Award for scaling OnTask across multiple faculties. His contributions span over 30 years, including founding roles at The Open University’s Knowledge Media Institute and innovations in Open Educational Resources (OER), SocialLearn, and FutureLearn platforms. Notable awards: 2024 Student Experience Award (OnTask), Fellow of the Royal Society of Arts (RSA), DEFI STRI Researcher at University of Cambridge Education: B.Sc. in Psychology (York), M.Sc. in Ergonomics (UCL), PhD in Human-Computer Interaction (York) He leads multidisciplinary collaborations with teams across Business, Law, and Education faculties, pioneering tools like Theme Explorer and Qreframer bot. His recent focus on the "metacrisis" reframes educational technology’s role in addressing global systemic challenges through transdisciplinary approaches.
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Massachusetts Institute of TechnologyUnited States
Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.
Allison Koenecke is an Assistant Professor of Information Science at Cornell Tech and a field faculty member in Computer Science at Cornell University. Previously, she was a postdoctoral researcher at Microsoft Research New England and completed her PhD at Stanford University’s Institute for Computational & Mathematical Engineering. Her research focuses on algorithmic fairness, computational social science, and causal inference in public health, addressing disparities in automated systems like speech recognition and policy decision-making. Education : PhD, Stanford Institute for Computational & Mathematical Engineering MA/MS, Stanford University BA/BS, Massachusetts Institute of Technology Research Interests : Dr. Koenecke’s work bridges economics and computer science, emphasizing equity in AI systems. Key areas include: Algorithmic bias in speech recognition (e.g., racial disparities in voice assistants) Fairness in policy tools like environmental justice data systems Causal analysis in public health interventions Ethical implications of large language models in education Media & Impact : Her research has been featured in outlets like New York Times , Science , and Scientific American . Notable studies include exposing racial gaps in speech-to-text systems and advocating for inclusive dataset development. She also explores societal impacts of AI in education and governance. Awards : Sloan Research Fellow in Computer Science Forbes 30 Under 30 in Science NSF Awards Cornell CIS Teaching Excellence Award (2024) Teaching & Outreach : She teaches courses like Designing Fair Algorithms and Data Science for Global Development , emphasizing interdisciplinary collaboration. Her PhD Professionalization course addresses hidden curricula in academia. She advises on AI ethics for nonprofits, tech companies, and government agencies.
Michael Potter is Professor of Logic at the Faculty of Philosophy , University of Cambridge, and a Life Fellow at Fitzwilliam College. Previously at Balliol College, Oxford (D.Phil. in pure mathematics), he has held research fellowships at St Andrews, Harvard, and Stirling University (AHRC-funded). His work bridges historical and systematic philosophy, focusing on History of analytic philosophy (Frege, Russell, Wittgenstein, Ramsey) Philosophy of mathematics and logic Philosophy of religion Potter's research has produced major works like Set Theory and its Philosophy (OUP 2004) and The Rise of Analytic Philosophy (Routledge 2019), with significant contributions to understanding the Metaphysical underpinn't> of the Tractatus Neo-Fregean logicism Paradoxes in mathematical foundations He has supervised research on topics spanning dialetheism, predicative mathematics, and modal ontological arguments. Scientific awards include the AHRC Senior Research Fellowship (2004-2005). His recent publications analyze Transcendental arguments in Wittgenstein Sortition-based democratic theory Philosophical implications of Ramsey's infinite proofs via peer-reviewed chapters and journal articles.
Massachusetts Institute of TechnologyUnited States
Connor Coley is the Henri Slezynger (1957) Career Development Assistant Professor at the Massachusetts Institute of Technology (MIT) School of Engineering. His research bridges chemistry and machine learning, focusing on autonomous molecular discovery, predictive chemistry, and laboratory automation. Education: Ph.D., MIT (2019) M.S.CEP., MIT (2016) B.S., Caltech (2014) Research Interests: Dr. Coley’s work centers on domain-informed machine learning for chemistry, computer-aided molecular design, and autonomous laboratories. Key themes include predictive modeling of chemical reactivity, optimization of synthesis pathways, and integration of AI with experimental data for drug discovery and materials science. Publications: His recent articles highlight advancements in AI-driven reaction prediction, molecular representation learning, and laboratory automation. Trends include applications of Bayesian optimization, contrastive learning, and diffusion models to chemical discovery. Scientific Awards: Camille Dreyfus Teacher-Scholar Award (2025) James W. Swan Outstanding Faculty (2025) Schmidt Futures AI2050 Early Career Fellow (2022) NSF CAREER Award (2021) Forbes 30 Under 30: Healthcare (2019) Software & Tools: He leads the open-source ASKCOS software suite for synthesis planning, adopted by 35,000+ chemists and deployed at 15+ pharmaceutical companies. His team also develops tools for metabolomics and molecular representation learning.
David John Procter is a Professor of Organic Chemistry and Head of the Department of Chemistry at the University of Manchester. His career includes academic roles at the University of Glasgow (Lecturer, Senior Lecturer) and a Readership at the University of Manchester, where he became a Professor in 2008. His research focuses on developing new synthetic methods, catalysis, and materials chemistry, with applications in drug discovery, biocatalysis, and organic electronics. Education: BSc Chemistry (University of Leeds, 1992), PhD (1995, supervised by Prof. Christopher Rayner). Postdoctoral work: Florida State University (Prof. Robert Holton, Taxol analog synthesis). Research interests include samarium diiodide-mediated reactions, metal-free coupling processes, and sustainable synthesis methods. He leads projects funded by EPSRC, Industry (30 grants), and international collaborations. Awards include the EPSRC Established Career Fellowship (2015–2020), Bader Prize (2014), and Young Heterocyclic Chemist Award (2015). Key contributions: Total synthesis of natural products (e.g., pleuromutilin), development of copper-catalyzed multicomponent couplings, and innovative methods for organic materials. His work aligns with UN Sustainable Development Goals related to affordable and clean energy and responsible consumption. Collaborations span academic and industrial partnerships in chemistry, physics, and biology. He supervises 60+ students and contributes to the Organic Materials Innovation Centre (OMIC). His group’s research is detailed at proctergroupresearch.com .
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Jan Madsen is a Professor at DTU Compute, Technical University of Denmark, and Head of the Embedded Systems Engineering section. His research focuses on system-level modeling and design of embedded computing systems, particularly cyber-physical systems, microfluidic biochips, and synthetic biology applications. Develops design automation tools and methodologies for embedded systems Supervises numerous PhD students and leads major research projects Research Interests Key areas include: Embedded systems-on-a-chip Cyber-Physical Systems (Internet-of-Things) Microfluidic Lab-on-Chip devices Synthetic biology with molecular computing Design, modeling, and optimization of complex systems Scientific Awards DATE Fellow (2019) IEEE CEDA Outstanding Recognition (2019) DTU Scientific Advise Award (2013) Best Paper Awards at MECO (2013) and CASES (2009) Jorck’s Foundation Research Award (1995) Publications His 14+ journal papers and 115+ conference papers demonstrate expertise in: SystemC-based modeling frameworks Energy-aware sensor networks Self-healing eDNA architectures Microfluidic biochip synthesis RTOS modeling and MPSoC exploration
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
